The effect of butaselmevit and clozaverm A on the antioxidant status of cows in experimental fasciolosis

Fasciolosis is one of the most dangerous helminthiasis, causing significant economic damage to farms. Therefore, the study aimed to investigate the effect of clozaverm A and butaselmevit on the antioxidant status of cows in experimental fasciolosis. Fifteen 4-5-year-old cows of the black and speckled breed were selected for the experiments, from which three groups were formed, with five animals in each. Animals of the control group were experimentally infected with adolescents. Cows of the first experimental group in experimental fasciolosis were administered intramuscularly clozaverm A at a dose of 0.5 ml per 10 kg of body weight. In animals of the second experimental group, in experimental fasciolosis, clozaverm A was administered intramuscularly at a dose of 0.5 ml of the drug per 10 kg of body weight of animals and butaselmevit at a dose of 10 ml of the drug per animal. In experimental fasciolosis in the blood of cows, we note an increase in the processes of lipid peroxidation, as indicated by elevated levels of lipid hydroperoxides and TBA-active products. Fasciola inhibits the activity of enzymes of the antioxidant defense system in the liver of the hosts, as indicated by a decrease in the activity of catalase by 23.4 % (P < 0.001) superoxide dismutase by 24.6 % (P < 0.001). The obtained data indicate that under the influence of clozaverm A and butaselmevit in the body of experimental cows with experimental fasciolosis is the normalization of redox processes and reduces the level of LPS products, the intoxication of the body. The use of clozaverm A and butaselmevit in cows with experimental fasciolosis improved the antioxidant status of their body, which was accompanied by an increase in blood superoxide dismutase activity by 31.6 % (P < 0.001) and catalase by 30.1 % (P < 0.001), as well as suppression of intensity peroxide oxidation of lipids, reducing the level of lipid hydroperoxides by 31.5 % (P < 0.001), TBA-active products by 18.1 % (P < 0.001). Inhibition of lipid peroxidation processes in the treatment of animals with Clozaverm A and Butaselmevit is due to the activation of metabolic processes in the body, which involve enzymes, including antioxidant enzymes that catalyze the oxidation and phosphorylation functions, and bone marrow.